SHH and neoplasm: While much of the current approaches to treat MB focus on Shh antagonists such as vismodegib (Morrissy et al., 2017; Zarei et al., 2017; Tan et al., 2018), the insight that starting points of MB are pre-migratory granule cell precursors suggest a possible additional approach: induce premature migration that may deplete EGL and truncate the numbers of granule cells, which should certainly reduce tumor progression.